T cell engagers targeting CD19 to treat B cell malignancies, and beyond

Copyright: © 2022 Yan X. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. In the past decade, a tremendous progress has been made in developing T cell engaging bispecific antibodies (BsAbs) targeting CD19 to treat B cell malignancies. The T cell engaging bispecific molecule binds to CD3 on a T cell and a tumor-associated antigen (TAA) on a target cell and redirects the T cell to a specific target cell bypassing the MHC restriction mechanism, leading to the formation of immune synapse between the T cell and target cell and target cell lysis [1,2].